Patients in England and Wales with rare disease familial chylomicronaemia syndrome (FCS) will soon have a new treatment ...

Bayer has looked internally for a new chief medical officer, appointing Dr Christoph Koenen to the position in addition to ...

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on a new combination ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, ...

Clinical trial recruitment challenges rarely stem from a lack of strategy. Today’s sponsors are investing more heavily in data, feasibility, and patient intelligence to identify the right sites and ...

Hundreds of people with a rare and aggressive form of leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after it was recommended for routine commissioning by the NHS.

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...